Condition (MeSH)
Osteoradionecrosis
ClinicalTrials.gov lists 20 trials for Osteoradionecrosis or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
20 of the 20 trials are tagged with Osteoradionecrosis itself; the rest are tagged with a narrower condition beneath it.
When did Osteoradionecrosis trials start? (13)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 2 trials are registered to start in 2027 or later, and not listed here.
Trials over time, by phase
- Phase 1
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 2
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2025 | 1 |
| 2023 | 1 |
| 2021 | 2 |
| 2019 | 2 |
| 2018 | 1 |
| 2017 | 2 |
| 2016 | 1 |
| 2015 | 1 |
| 2014 | 2 |
| 2013 | 1 |
Showing 10 of 13 earlier years.
No forecast is made for this condition: it averages 0.6 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Osteoradionecrosis trials in? (7)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 1 |
| Phase 2/3 | 1 |
| Phase 3 | 2 |
| Phase 4 | 2 |
| Not applicable | 5 |
| Observational | 8 |
How many Osteoradionecrosis trials are recruiting? (6)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 2 |
| Recruiting | 4 |
| Completed | 7 |
| Terminated | 2 |
| Withdrawn | 1 |
Showing 5 of 6 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which drugs are being tested for Osteoradionecrosis? (1)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Platelet Rich Fibrin | 1 |
Interventions as named in the registry (9)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Hyperbaric Oxygen | 3 |
| Radiotherapy | 2 |
| modified PENTOCLO (mPENTOCLO) | 1 |
| Contrast agent | 1 |
| sham mPENTOCLO | 1 |
Showing 5 of 9 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which publications cover Osteoradionecrosis? (49)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Osteoradionecrosis incidence in pre-radiation teeth extractions: A prospective study. | Oral diseases | 2024 | Yes |
| Exposed bone in patients with head and neck cancer treated with radiation therapy: An analysis of the Observational Study of Dental Outcomes in Head and Neck Cancer Patients (OraRad). | Cancer | 2022 | Yes |
| Intraosseous microdialysis for bone free flap monitoring in head and neck reconstructive surgery: A prospective pilot study. | Microsurgery | 2020 | Yes |
| Radiation-related caries: current diagnostic, prognostic, and management paradigms. | Oral surgery, oral medicine, oral pathology and oral radiology | 2020 | Yes |
| Incidence of new carious lesions and tooth loss in head and neck cancer patients: a retrospective case series from a single unit. | British dental journal | 2020 | Yes |
Showing 5 of 49 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: lead sponsors, serious adverse events in this condition's trials, prevalence, rare-disease identity, and sub-conditions in mesh.